Breaking News
Get 45% Off 0
It’s Here: WarrenAI - Your Personal Financial AI Researcher >>>
Try WarrenAI Now
Close

Abbisko Cayman Ltd (2256)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
6.84 +0.12    +1.79%
17/04 - Closed. Currency in HKD
Type:  Equity
Market:  Hong Kong
ISIN:  KYG0028A1085 
  • Volume: 3,688,000
  • Bid/Ask: 6.83 / 6.86
  • Day's Range: 6.56 - 6.97
Abbisko Cayman 6.84 +0.12 +1.79%

Abbisko Cayman Company Profile

 
Explore the Abbisko Cayman company profile for core details about Abbisko Cayman, assess Abbisko Cayman company details, including a description of the company, key contact information, and insights into the top executives. Discover the company's operations and leadership to better understand its role in the industry.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Abbisko Cayman Limited, an investment holding company, engages in the research and development of pharmaceutical products in the People’s Republic of China. The company develops Pimicotinib, which is in Phase III clinical trial for the treatment of tenosynovial giant cell tumor; Irpagratinib for the treatment of hepatocellular carcinoma; ABSK043 that is in Phase I clinical trial for the treatment of non-small cells lung cancer; and ABSK061 for the treatment of solid tumors. It also develops Fexagratinib, which is in Phase II clinical trial for the treatment of urothelial carcinoma; ABSK121, a small molecule FGFR inhibitor that targets both wild-type and mutations of FGFR1-3; ABSK112, an EGFR Exon20ins inhibitor with selectivity over wild-type EGFR and brain-penetration activity; Mavorixafor, an orally bioavailable CXCR4 modulator; and ABSK051, a small molecule CD73 inhibitor for the treatment of various tumor types, such as lung and pancreatic cancer. In addition, the company develops ABSK012, which is in Phase I clinical trial for treatment of soft tissue sarcoma; ABK131, a selective MTA-cooperative and brain-penetrant PRMT5 inhibitor; ABK3376, which is in Phase I clinical trial for the treatment of NSCLC harboring the EGFR-C797S mutation; and ABSK141, an orally bioavailable small-molecule KRAS-G12D inhibitor. Abbisko Cayman Limited was founded in 2016 and is headquartered in Shanghai, the People’s Republic of China.

Contact Information

Address Building 3, No. 898 Halei Road
Zhangjiang Hi-Tech Park Pudong New Area Shanghai,
China
Phone 86 21 6891 2098
Fax -

Top Executives

Name Age Since Title
Piaoyang Sun 66 2021 Independent Non-Executive Director
Yao-Chang Xu 68 2016 Founder, Chairman of the Board & CEO
Jing Ji 54 2021 Chief Medical Officer & Executive Director
Hongping Yu 57 2016 Co-Founder, Jt Co Secretary, Senior VP of Chemistry, Chief Scientific Officer & Executive Director
Hongbin Sun 50 2021 Independent Non-Executive Director
Hoi Yam Chui 57 2025 Independent Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

2256 Comments

Write your thoughts about Abbisko Cayman Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email